HomeCompareTRVN vs PLD

TRVN vs PLD: Dividend Comparison 2026

TRVN yields 18018.02% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRVN wins by $18633001307266260992.00M in total portfolio value
10 years
TRVN
TRVN
● Live price
18018.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$18633001307266260992.00M
Annual income
$18,431,768,966,926,280,000,000,000.00
Full TRVN calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — TRVN vs PLD

📍 TRVN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRVNPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRVN + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TRVN pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRVN
Annual income on $10K today (after 15% tax)
$1,531,531.53/yr
After 10yr DRIP, annual income (after tax)
$15,667,003,621,887,337,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, TRVN beats the other by $15,667,003,621,887,337,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRVN + PLD for your $10,000?

TRVN: 50%PLD: 50%
100% PLD50/50100% TRVN
Portfolio after 10yr
$9316500653633130496.00M
Annual income
$9,215,884,483,463,140,000,000,000.00/yr
Blended yield
98.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

TRVN
Analyst Ratings
9
Buy
5
Hold
Consensus: Buy
Altman Z
-48.2
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRVN buys
0
PLD buys
0
No recent congressional trades found for TRVN or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRVNPLD
Forward yield18018.02%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$18633001307266260992.00M$6.50M
Annual income after 10y$18,431,768,966,926,280,000,000,000.00$5,256,436.18
Total dividends collected$18619711198521020416.00M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: TRVN vs PLD ($10,000, DRIP)

YearTRVN PortfolioTRVN Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$1,812,502$1,801,801.80$11,255$555.24+$1.80MTRVN
2$307,151,434$305,212,057.22$13,062$1,018.59+$307.14MTRVN
3$48,667,022,851$48,338,370,816.14$15,903$1,926.67+$48667.01MTRVN
4$7,210,053,431,136$7,157,979,716,686.14$20,839$3,823.32+$7210053.41MTRVN
5$998,798,584,418,300$991,083,827,246,983.60$30,464$8,166.08+$998798584.39MTRVN
6$129,380,351,742,642,780$128,311,637,257,315,230.00$52,054$19,457.30+$129380351742.59MTRVN
7$15,672,057,030,122,314,000$15,533,620,053,757,686,000.00$109,886$54,188.93+$15672057030122.20MTRVN
8$1,775,286,122,699,574,700,000$1,758,517,021,677,343,500,000.00$304,030$186,451.18+$1775286122699574.50MTRVN
9$188,067,607,794,372,840,000,000$186,168,051,643,084,300,000,000.00$1,166,125$840,813.32+$188067607794372832.00MTRVN
10$18,633,001,307,266,260,000,000,000$18,431,768,966,926,280,000,000,000.00$6,504,190$5,256,436.18+$18633001307266260992.00MTRVN

TRVN vs PLD: Complete Analysis 2026

TRVNStock

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Full TRVN Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this TRVN vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRVN vs SCHDTRVN vs JEPITRVN vs OTRVN vs KOTRVN vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.